Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective Phase III Multi-center Open-label Study of the Efficacy, Safety, and Acceptability of Mifepristone 50 mg Once-weekly as a Contraceptive

NCT06394999 is registered in ClinicalTrials.gov with Leiden University Medical Center as lead sponsor.

NCT NCT06394999
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06394999 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective Phase III Multi-center Open-label Study of the Efficacy, Safety, and Acceptability of Mifepristone 50 mg Once-weekly as a Contraceptive
Lead sponsor
Leiden University Medical Center
Phase
Phase 3
Overall status
Active, not recruiting
Start date
May 2, 2025
Completion date
January 1, 2028
Enrollment
615 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

female contraception